ÂÜÀòÂÒÂ×

Alberto Martinez has over 25 years of work experience, with a focus on clinical development and translational medicine. Alberto has held various leadership roles in pharmaceutical and biotechnology companies.

From 2020 to present, Alberto worked as a Senior Clinical Science Director at Silence Therapeutics plc. Prior to that, they served as Senior Director of Clinical Development at Orchard Therapeutics from 2018 to 2020.

Before joining Orchard Therapeutics, Alberto worked as a Clinical Development Director at Albumedix Ltd from 2017 to 2018. Alberto also served as a Drug Rescue Manager at Almac Group in 2016.

In 2014, Alberto had two roles. Alberto was the Director of Translation Medicine and Clinical Pharmacology at Daiichi Sankyo Development Ltd from 2014 to 2016. Alberto was also a Director at Translate Consultants, where they provided advisory and project management services in translational medicine and drug development.

From 2008 to 2013, Alberto held the position of Preclinical and Clinical Operations Director at Syntaxin Ltd. Alberto was responsible for leading and managing programs in translational research and drug development.

Alberto's earlier experience includes working as a Consultant at Aspreva Pharmaceuticals from 2006 to 2007, where they evaluated programs, designed clinical development plans, and led project management and evaluation tasks. Alberto also worked as a Project Leader and Team Leader at Syngenta Biotechnology Inc from 1998 to 2006, leading multidisciplinary teams and overseeing the development of novel biologic therapeutics.

Alberto started their career as a Post Doc at Zeneca from 1994 to 1998.

Alberto Martinez has a diverse education history. Alberto started their academic journey in 1983 at the University of Waterloo, where they pursued a Bachelor of Science Honors degree with a focus on Biology and a minor in Chemistry. Alberto completed this program in 1987. Following this, they attended The University of Edinburgh from 1987 to 1991 and obtained a Ph.D. in Molecular Biology and Genetics. In 2006, Alberto enrolled at the University of Liverpool and accomplished a Master of Business Administration degree by 2009. Later, from 2009 to 2011, they attended the University of Basel and earned a Postgraduate Advance Diploma in Pharmaceutical Medicine.